Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
Open Access
- 1 February 1990
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 29 (2) , 248-253
- https://doi.org/10.1111/j.1365-2125.1990.tb03628.x
Abstract
The kinetics at a single oral dose (400 mg) of quinidine were studied in four extensive metabolizers (EM) and four poor metabolizers (PM) of sparteine. The clearance of quinidine by 3-hydroxylation was significantly lower in PM than in EM, but the difference was small (25- 30%). This finding suggests that 3-hydroxylation, in part, is catalyzed by the same isoenzyme of cytochrome P450, P450db1 which oxidizes sparteine. Otherwise, no significant phenotypic differences in total or metabolic clearance were found and it is concluded that the metabolism of quinidine is largely carried out by P450 isoenzymes different from P450db1. A biexponential decline in the log plasma quinidine concentration vs time curves was observed in all subjects, and the mean elimination half-life was 11-12 h. This is about twice as long as generally reported in the literature.This publication has 24 references indexed in Scilit:
- Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in manBiochemistry, 1988
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Sparteine oxidation is practically abolished in quinidine-treated patients.British Journal of Clinical Pharmacology, 1986
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- A human cytochrome P-450 characterized by inhibition studies as the sparteine–debrisoquine monooxygenaseCanadian Journal of Physiology and Pharmacology, 1984
- Pharmacokinetics of quinidine and three of its metabolites in manJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Clinical Pharmacokinetics of QuinidineClinical Pharmacokinetics, 1980